Recent Research Analysts’ Ratings Changes for Adaptive Biotechnologies (ADPT)

A number of research firms have changed their ratings and price targets for Adaptive Biotechnologies (NASDAQ: ADPT):

  • 7/23/2019 – Adaptive Biotechnologies is now covered by analysts at BTIG Research. They set a “buy” rating and a $46.00 price target on the stock.
  • 7/22/2019 – Adaptive Biotechnologies is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $45.00 price target on the stock.
  • 7/22/2019 – Adaptive Biotechnologies is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
  • 7/22/2019 – Adaptive Biotechnologies is now covered by analysts at Cowen Inc. They set an “outperform” rating on the stock.
  • 7/22/2019 – Adaptive Biotechnologies is now covered by analysts at Goldman Sachs Group Inc. They set a “neutral” rating and a $32.00 price target on the stock.
  • 7/22/2019 – Adaptive Biotechnologies is now covered by analysts at Guggenheim. They set a “buy” rating and a $47.00 price target on the stock.
  • 7/22/2019 – Adaptive Biotechnologies is now covered by analysts at Bank of America Corp. They set a “buy” rating and a $45.00 price target on the stock.

Adaptive Biotechnologies stock opened at $37.33 on Monday. Adaptive Biotechnologies Corporation has a fifty-two week low of $36.21 and a fifty-two week high of $51.00.

In related news, insider Nancy Louise Hill acquired 11,200 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were purchased at an average cost of $20.00 per share, with a total value of $224,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Viking Global Performance Llc acquired 250,000 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were bought at an average cost of $20.00 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders bought 262,200 shares of company stock worth $5,244,000.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Hudock Capital Group LLC acquired a new stake in shares of Adaptive Biotechnologies in the second quarter worth $62,000. AGF Investments Inc. acquired a new stake in shares of Adaptive Biotechnologies in the second quarter worth $121,000. SG Americas Securities LLC acquired a new stake in shares of Adaptive Biotechnologies in the second quarter worth $724,000. Alpine Group USVI LLC acquired a new stake in shares of Adaptive Biotechnologies in the second quarter worth $966,000. Finally, Kornitzer Capital Management Inc. KS acquired a new stake in shares of Adaptive Biotechnologies in the second quarter worth $1,690,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals.

Featured Story: Stock Symbols and CUSIP Explained

Receive News & Ratings for Adaptive Biotechnologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.